Genotyping of 25 leukemia-associated genes in a single work flow by next-generation sequencing technology with low amounts of input template DNA

Clinical Chemistry

Volumn 59, Issue 8, 2013, Pages 1238-1250

  Rinke, Jenny ^a   Schäfer, Vivien ^a   Schmidt, Mathias ^a   Ziermann, Janine ^a   Kohlmann, Alexander ^b   Hochhaus, Andreas ^a   Ernst, Thomas ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AMPLICON; ARTICLE; BONE MARROW EXAMINATION; CLINICAL ARTICLE; COHORT ANALYSIS; DNA SEQUENCE; DNA TEMPLATE; EXON; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; LEUKEMIA; MALE; MEDICAL TECHNOLOGY; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; MYELOPROLIFERATIVE NEOPLASM; NEXT GENERATION SEQUENCING; POLYMERASE CHAIN REACTION; RNA SPLICING; SEQUENCE ANALYSIS;

AGED; AGED, 80 AND OVER; DNA; GENOME, HUMAN; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MIDDLE AGED; MUTATION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 84880884037     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.204099     Document Type: Article

References (21)

1. Döhner H, Gaidzik VI. Impact of genetic features on treatment decisions in AML. Hematology Am Soc Hematol Educ Program 2011;2011:36-42.
2. Graubert T, Walter MJ. Genetics of myelodysplastic syndromes: new insights. Hematology Am Soc Hematol Educ Program 2011;2011:543-9.
3. Cross NC. Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2011;2011:208-14.
4. Cazzola M, Malcovati L, Invernizzi R. Myelodysplastic/myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2011;2011: 264-72.
5. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478:64-9.
6. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011;365:1384-95.
7. Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011;118:6239-46.
8. Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, Kazak B, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010;28:3858-65.
9. Grossmann V, Kohlmann A, Eder C, Haferlach C, Kern W, Cross NC, et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in -80% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia 2011;25:877-9.
10. Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011;118:3932-41.
11. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:2496-506.
12. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366:1079-89.
13. Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012;120:3080-8.
14. Hawkins TL, Detter JC, Richardson PM. Whole genome amplification- applications and advances. Curr Opin Biotechnol 2002;13:65-7.
15. Spits C, Le Caignec C, De Rycke M, Van Haute L, Van Steirteghem A, Liebaers I, et al. Wholegenome multiple displacement amplification from single cells. Nat Protoc 2006;1:1965-70.
16. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937-51.
17. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 p.V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162-8.
18. Grossmann V, Schnittger S, Schindela S, Klein HU, Eder C, Dugas M, et al. Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology. J Mol Diagn 2011;13:129-36.
19. Kohlmann A, Klein HU, Weissmann S, Bresolin S, Chaplin T, Cuppens H, et al. The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. Leukemia 2011;25:1840-8.
20. Yokota M, Tatsumi N, Tsuda I, Yano I. DNA extraction and amplification from Giemsa-stained blood smears. J Clin Lab Anal 1995;9:387-91.
21. Pinard R, de Winter A, Sarkis GJ, Gerstein MB, Tartaro KR, Plant RN, et al. Assessment of whole genome amplification-induced bias through highthroughput, massively parallel whole genome sequencing. BMC Genomics 2006;7:216-37.